Final Results

RNS Number : 4531K

Edinburgh Worldwide Inv Trust PLC

14 December 2018

 

RNS Announcement: Preliminary Results

Edinburgh Worldwide Investment Trust plc

Legal Entity Identifier: 213800JUA8RKIDDLH380

Regulated Information Classification: Additional regulated information required to be disclosed under the laws of a Member State of the European Union.

The following is the preliminary statement for the year to 31 October 2018 which was approved by the Board on 13 December 2018.

¾  Over the year to 31 October 2018, the Company's net asset value per share, cum income with debt at fair value, increased by 14.9% and the share price by 19.0%. The comparative index, the S&P Global Small Cap Index^* total return, increased by 0.1% in sterling terms.

¾  No final dividend is being paid. The Company's objective remains that of generating capital growth. Should the level of underlying income increase in future years, the Board will seek to distribute the minimum permissible to maintain investment trust status.

¾  A number of the Company's holdings contributed to the positive performance, notably: Ocado, an online grocery company, Wayfair, a US online furniture and homeware retailer, and STAAR Surgical, a US developer and manufacturer of visual implants.

¾  As at the year end, the Company held five unlisted investments accounting for 3.2% of total assets (2017 - 2.1% of total assets in three holdings). As part of the business of the Company's AGM, the Board is seeking shareholder approval to increase the permissible limit in unlisted investments, from 5% of total assets at the time of initial investment at present, to 15%.

¾  The Board is seeking shareholder approval at the Company's AGM to subdivide each existing ordinary share of 5p nominal value into five ordinary shares of 1p nominal value.

Summary

Edinburgh Worldwide aims to achieve long term capital growth by investing in listed companies throughout the world. The Trust has total assets of £521.1 million (before deduction of loans of £48.6 million) as at 31 October 2018.

Edinburgh Worldwide is managed by Baillie Gifford & Co Limited, the Edinburgh based fund management group with around £180 billion under management and advice as at 13 December 2018.

Past performance is not a guide to future performance.

The value of an investment and any income from it is not guaranteed and may go down as well as up and investors may not get back the amount invested. This is because the share price is determined by the changing conditions in the relevant stockmarkets in which the Company invests and by the supply and demand for the Company's shares. Investment in investment trusts should be regarded as medium to long-term. You can find up to date performance information about Edinburgh Worldwide on the Edinburgh Worldwide page of the Managers' website at http://www.edinburghworldwide.co.uk‡

^*    See disclaimer at the end of this announcement.

‡    Neither the contents of the Managers' website nor the contents of any website accessible from hyperlinks on the Managers' website (or any other website) is incorporated into, or forms part of, this announcement.

14 December 2018

For further information please contact:

Anzelm Cydzik, Baillie Gifford & Co                        Roland Cross, Director, Four Broadgate

Tel: [phone]                                                     Tel: [phone] or 07831 40130

Chairman's Statement

Performance

In the year to 31 October 2018, the Company's net asset value ('NAV') per share, when calculated by deducting borrowings at fair value, increased by 14.9% and the share price by 19.0%, both in total return terms. The comparative index, the S&P Global Small Cap Index^* total return, increased by 0.1% in sterling terms during this period. Over the course of the financial year the share price averaged a 1.2% premium to net assets, with borrowings deducted at fair value. Portfolio turnover was 12.6% compared to 13.2% in 2017 and the ongoing charges have reduced to 0.81% from 0.87%.

The good relative and absolute performance was driven by a number of holdings, most notably Ocado, an online grocery company, Wayfair, a US online furniture and homeware retailer, and STAAR Surgical, a US developer and manufacturer of visual implants. On balance, the fundamental performance of the holdings in the portfolio continues to progress as hoped. Greater detail on this can be found within the Managers' Review below.

Share Buybacks, Treasury and Issuance

The Company will once again be seeking to renew its share buyback, issuance and treasury share authorities. The buyback facility is sought to allow the Company to buy back its own shares when the discount is substantial in absolute terms and relative to its peers. Issuance, either from treasury or of new shares, will only be undertaken at a premium to the prevailing cum income NAV, with debt calculated at par, in order to satisfy natural market demand. This would enhance the NAV per share for existing shareholders as well as dilute ongoing costs and help with the trading liquidity of the shares of the Company.

Over the course of the last financial year, the Company has been able to issue over 8.2 million new shares at a premium to its NAV, raising net proceeds of £71.3 million and increasing the NAV per share by 0.34%. This equates to 16.8% of the issued share capital at the start of the year. This, along with good investment performance and the benefits of a tiered management fee, has contributed to the reduction in the Company's ongoing charges for the year.

Unlisted Investments and Investment Policy

At present, the Company is permitted to invest up to 5% of total assets in unlisted equity investments, in aggregate, at time of acquisition. As part of the business of the Company's Annual General Meeting, the Board is seeking shareholder approval to increase the permissible limit to 15% of total assets at the time of initial investment

As at the Company's year end, the portfolio weighting in unlisted investments stood at 3.2% of total assets, invested in five holdings (2017 - 2.1% of total assets in three holdings). There were three new unlisted purchases during the year: Reaction Engines, a UK company that designs and manufactures very advanced heat exchangers; Akili Interactive Labs, a US company utilising technology for healthcare; and KSQ Therapeutics, a US preclinical-stage biotechnology company focusing on oncology and immuno-oncology product development. Unity Biotechnology, which was bought in October 2016, listed on Nasdaq in May this year.

Your portfolio managers remain alert to further special and high potential opportunities not widely accessible through public markets. Although they still have 1.8 percentage points of headroom to invest in unlisted investments, at points over 2018 they have had concerns that the 5% limit could curtail investments in potentially very exciting opportunities.

In 2014, the Company broadened its investment policy to allow a greater level of investment in companies at a much earlier point in their growth cycle. As part of this, the amount permissible to be invested in unlisted investments was increased from 1% to 5% of total assets, at time of initial investment. Since then, Baillie Gifford has established a dedicated investment team focused on analysing and investing in unlisted investments and currently has £1.5 billion invested in 48 private holdings across 10 countries to varying extents. In addition, Luke Ward, one of Edinburgh Worldwide's two deputy portfolio managers has been spending an increasing amount of time analysing unlisted opportunities alongside other colleagues at Baillie Gifford, specifically those companies that fit Edinburgh Worldwide's policy and objective.

Considering the increasing quantum of interesting unlisted investment opportunities emerging that fit the portfolio managers' criteria for investment, namely investing in immature but innovative businesses that are best positioned and able to prosper in a rapidly technologically evolving world and that will typically, although not necessarily, have a market valuation of less than US$5billion at time of initial investment, the Board is seeking shareholder approval to increase the permissible limit in unlisted investments to 15% of total assets at the time of initial investment.

Sub Division of Ordinary Shares of 5p Nominal Value ('share split')

Over the 12 months to 31 October 2018, the Company's share price has risen from 690.50p to 822.00p and at points to over 1000.00p. Over recent years, the Board has observed a marked shift in the composition of the Company's share register; the majority of investors now represent, or are, individuals investing on an advised or direct basis, particularly through investment platforms, on a regular basis. One of the disadvantages of a high share price is that regular savers, who often make small monthly share purchases, may find that a considerable proportion of their monthly payment remains uninvested. In addition, a higher share price results in a wider bid/offer spread at which shares can be bought and sold. Reducing the share price, through increasing the number of shares in issue by way of a share split, and reducing the amount of uninvested cash from regular savers, should help improve trading liquidity to the benefit of all. Consequently, the Board is seeking shareholder approval to subdivide each existing ordinary share of 5p nominal value into five ordinary shares (of 1p nominal value). If approved, the number of shares held by each investor will increase five fold and the share price will reduce to one fifth of its prior amount, resulting in no change to the aggregate value of the holding. For shareholders who hold their shares in certificated form, new share certificates will be issued and the old certificates will become invalid. Further details of the proposed share split are set out on page 22 of the Annual Report and Financial Statements.

Borrowings

The extent and range of equity gearing is discussed by the Board and Managers at each Board meeting. Both parties agree that the Company should typically be geared to equities to maximise potential returns, with the current aspirational parameters set at +5% to +15%. Over the year, the invested equity gearing ranged between 1.3% and 8.9%, and stood at 5.3% at the financial year end (2017 - 8.6%). Despite undertaking a new £25 million borrowing facility during the year, the level of equity gearing has tended to be at the lower end of the spectrum due largely to the rate of asset appreciation and amount of stock issuance.

Currently, the Company has a five year fixed rate multi-currency loan from National Australia Bank Limited, expiring in September 2019, with drawings of €9.4 million, US$25.6 million and £7.5 million, with a weighted average interest rate of 2.8%. In addition, the Company has a further £25 million five year revolving multi-currency facility with National Australia Bank Limited, expiring in June 2023. At present, drawings under this facility are €2.1 million, US$9.9 million and £3.1 million, with an average interest rate of 3.4%.

Earnings and Dividend

The Company's objective is to generate capital growth and investors should not expect any income from this investment. This year the net revenue return per share was a negative 0.95p (2017 - positive 0.30p due largely to a one-off refund of French withholding tax and associated interest). As the revenue account for 2018 is running at a deficit, the Board is recommending that no final dividend be paid. Should the level of underlying income increase in future years, the Board will seek to distribute the minimum permissible to maintain investment trust status by way of a final dividend.

Increase in Ceiling on Directors' Fees

The Company's Articles of Association provides that the aggregate remuneration paid to the Directors shall not exceed £150,000 per annum, or such larger amount agreed by the Company by ordinary resolution. Based on the level of aggregate remuneration expected to be paid for the financial year ending 31 October 2019 (£130,500 - being £34,500 for the Chairman, £23,000 for each Director and an additional £4,000 for the Chairman of the Audit and Management Engagement Committee), should the Board wish to appoint a new Director the aggregate fees would likely exceed the current authorised limit. Accordingly, it is proposed that, pursuant to Resolution 6, as set out in the Notice of Annual General Meeting, the maximum aggregate amount of fees payable to the Directors be increased to £200,000 per annum in aggregate.

Investment Outlook

As stated last year, the ability to identify the companies that value innovation and have the capability to develop commercial opportunities around it, is key to unearthing the market leaders of the future and is a key focus for the managers. Such companies can be expected to thrive regardless of the underlying economic conditions. Nonetheless, the actions of investors often exhibit indiscriminate tendencies and immature growth companies can undergo notable price volatility. The structure of investment trusts permits their managers and discerning long term investors to take positions for the long term when the tide of money or sentiment depresses valuations. Rather than focus on macro economic developments, your managers will therefore continue to focus their efforts on picking growth companies that create and exploit investment opportunities and which exhibit excellent long term growth prospects and the potential for positive long term returns.

An overview of the portfolio is provided by the Managers below.

Annual General Meeting

The Annual General Meeting of the Company will be held at Baillie Gifford's offices in Edinburgh at 12 noon on Wednesday 23 January 2019. Further information on this and all the resolutions can be found on pages 53 and 54 of the Annual Report and Financial Statements. The Directors consider that all resolutions put to shareholders are in their and the Company's best interests as a whole and recommend that shareholders vote in their favour.

Douglas Brodie, the portfolio's lead manager, and Svetlana Viteva and Luke Ward, joint deputy portfolio managers, will give a prescntation and take questions. The Board will also be available to respond to any questions that you may have. I hope that you will be able to attend.

Henry CT Strutt

Chairman

13 December 2018

For a definition of terms see Glossary of Terms, note 10.

^*See disclaimer at the end of this announcement

Past performance is not a guide to future performance.
 

Managers' Review

For most of the Company's financial year to end of October 2018, equity markets were in robust form. As highlighted in the Interim Report, our sense was that investors were behaving broadly rationally, driven largely by fundamentals and with a reasonable ability to tolerate the inevitable 'noise' of macro events. It is the nature of modern equity markets that such periods will only ever be transient, hence the return of volatility and pangs of cyclically-driven anxiety in more recent months have not overly surprised us. Against this changing backdrop, the portfolio continued to perform well over the past year and, in aggregate, we continue to be very pleased with the operational performance of the holdings in the portfolio and in many cases we sense that it will continue to build at a very significant rate. Given the network effects and platform-based nature of many of these businesses, we believe that this positions them very well for the future. Our long-term growth-led investment style means we feel comparatively, yet comfortably, disconnected from the plethora of shorter-term factors that are currently combining to rebase markets downwards. Moreover, periodic market angst and the indiscriminate way in which this often manifests itself can frequently yield interesting investment opportunities for patient stock-picking investors. 

We had previously flagged the heightened level of corporate activity across the portfolio. Over the course of the past year four of the Company's holdings were acquired: the online fashion retailer YOOX Net-a-Porter was bought by Richemont; software company MuleSoft was taken over by Salesforce; genetic testing company Foundation Medicine was sold to Roche; and investment advisor Financial Engines was an acquisition for a private equity company. While the contribution from these acquired businesses was positive, it was comparatively modest for overall relative performance over the year; most of the performance can be attributed to stocks which we continue to own and are increasingly enthused by. In seeking to identify up-and-coming, innovative companies we recognise that some will inevitably carve out a commercial proposition and uniqueness that make them attractive to potential acquirers. It is typically an outcome that we do not actively favour. Rather, we prefer our most innovative holdings to remain independent as we believe this often maximises the likelihood of a business really succeeding and ultimately increasing the long-term returns that can be achieved.

The most significant contribution to performance over the year was Ocado, the online grocery company, where the announcement of several licensing deals with large incumbents around the world endorsed our view that it has the most compelling solution for selling online grocery at scale. The most notable of these licensing deals is with Kroger, the second largest grocer in the US. This could see up to 20 Ocado-powered warehouses built in the US over the coming years. It is a transformational event for Ocado and a clear endorsement of how forward-thinking supermarkets are approaching the changes in consumer habits. Another of our e-commerce companies, Wayfair, also produced strong returns over the 12 months. Wayfair's expertise in merchandising furniture and home furnishings presents challenges that are different to the grocery offering of Ocado, yet both companies are pioneers of a digital offering into their respective end markets. Whilst pleased with their progress thus far, what strikes us most is just how early these vast end markets are in their transition to online, and how their offerings are rapidly evolving to be ultimately better for consumers, not merely an alternative. STAAR Surgical and Teladoc, both relatively recent purchases in the healthcare area, yielded very strong returns. STAAR Surgical, a developer of vision correcting implantable lenses, benefited from strong growth of its offering in Asia plus the removal of regulatory hurdles. This now opens the vast potential within the US market. We see a great opportunity for the business both to take share from laser-based vision correction and to expand the market for vision correction to those with more pronounced short-sightedness. Teladoc is emerging as the dominant company in the nascent telemedicine industry. The use of digital technologies to guide both patients and doctors outside of conventional GP and hospital settings is an area that offers huge cost and efficiency gains for consumers, employers and payers. We think that, in broadening its offering from simple GP consultations towards chronic conditions, mental health and expert consultations, Teladoc is building a compellingly deep and sophisticated offering that could evolve to become the initial point of contact through which an individual will engage with the health system. 

Negative contributors to performance over the past year included several long-standing holdings. In many cases, this follows the stocks having been exceptionally strong performers in the previous year. We would highlight the drug development company Alnylam Pharmaceuticals, the financial market place LendingTree and fibre-laser manufacturer IPG Photonics. In all cases the weakness has been prompted by near-term, largely cyclical concerns which we believe ignore the longer-term potential of these businesses. With regard to Alnylam and LendingTree, we used the weakness to add to the positions.

Portfolio Update

We acquired a number of new holdings over the year. The purchases of BlackLine, Jianpu Technology, resTORbio and Reaction Engines were discussed in the Interim Report. New purchases in the second half of the year included the following:

Evolent Health is a US-based company which aims to change the way healthcare in the US is delivered. Hospitals and physician groups in the US are facing structural challenges driven by the growing pressure on the budgets for federal programmes such as Medicare and Medicaid. Other factors include an ongoing reduction in reimbursement rates and a push towards payment based on patients' outcomes rather than the number of procedures performed by the hospital. Evolent Health consults with hospitals and physician groups and sells them software to help them move away from a fee-for-service reimbursement model. The transition to value-based healthcare is still in its early days and the opportunity for Evolent Health ought to be very large. With a growing number of hospitals using its software, the company is developing a valuable data advantage and helping hospitals improve their productivity further as well as enabling them to take on insurance-style risk.

CyberArk Software is an Israeli cybersecurity company focused on protection for privileged accounts (powerful internal accounts that are managed by IT administrators or senior employees). These accounts are critical because they are the gate to sensitive information within an organisation, such as customers' credit cards, patients' medical records or employees' personal details. In layman's terms, what CyberArk does is to put the passwords associated with those accounts into a safe, monitor them and block the access if it suspects malicious behaviour. This is referred to as privileged account management (PAM), an area where CyberArk is recognised as the pioneer and market leader. As approximately 80% of security breaches involve compromised privileged accounts, we see significant scope for the company to grow industry penetration from its current low base.

Rubius Therapeutics is a biotechnology company that is seeking to use edited red blood cells to deliver therapeutic proteins. This is achieved by harvesting progenitor blood cells which are edited using techniques similar to gene therapy. Red blood cells have a number of advantages as delivery mechanisms; they have a long (but not indefinite) lifespan, are not attacked by the immune system, can be easily delivered through transfusion and offer the ability to create an 'off the shelf' product using Type 'O' cells. Rubius will shortly be entering clinical trials but has compelling pre-clinical data showing the approach could work in a wide range of disease settings ranging from genetic enzyme deficiency to autoimmunity.

Yext is a New York based software company. It helps businesses manage and synchronise digital information (from basics like opening hours to more frequently updated features like menus, in-store sale campaigns and special events) across a large and growing network of services such as Facebook, Siri, Google Maps, WeChat and others. Yext began through building a rational, up-to-date database focused on local content for small businesses. The value proposition of this was simple; small businesses could be in charge of their own information and therefore they could ensure consistency of that information across multiple different search or aggregation sites. Ongoing changes in how people search (i.e. more Alexa/Siri interfaces, more natural query and some dominant content aggregators) has pushed the topic of corporate 'knowledge management' much higher up the agenda. No longer is this simply about helping small businesses. Rather, the real growth is in helping bigger companies present an up-to-date view of their business, both internally and externally. The changing emphasis of the Yext offering from 'local' to 'fundamental' massively increases the addressable market and ultimately broadens the relevance of what it offers.

We increased the portfolio's unlisted exposure through initiating holdings in two private US companies, Akili Interactive Labs and KSQ Therapeutics. Akili Interactive Labs designs video games incorporating embedded therapeutic algorithms to both treat and monitor a range of neurological conditions. It is a business we have followed for several years and owned indirectly on account of it being one of the larger healthcare businesses within PureTech Health, the London-listed healthcare incubator, which is an existing holding for Edinburgh Worldwide. Akili recently demonstrated the clinical significance of its iPad-based therapeutic game, EVO, in a pivotal trial for ADHD, an achievement which we think makes it a real stand out in the emerging area of digital medicine. With growing evidence that game-based stimuli can drive long-term cognitive benefit, we are intrigued by the possibility of Akili taking its technology into many additional areas of neurological therapy. KSQ Therapeutics has found a way to identify and validate novel drug targets at scale using a rational platform-based approach. Initially their efforts are focused on cancer, but over the longer term the powerful platform could be pointed towards several other diseases. The company uses CRISPR technology to selectively cut (and hence destroy) specific genes within cells. Once the library of knocked-out cells has been produced, the individual clones can be extensively studied in a variety of in vitro and in vivo experiments with the goal of finding cells in which the destruction of a particular gene has yielded a profound impact on a disease. KSQ already has a range of targets which seem to show enhanced migration to, and significant reductions in, tumour volume relative to existing leading-edge immuno-oncology drugs.

The investments in Akili and KSQ are indicative of the interesting dynamic opportunities we are seeing in the unlisted area. Their addition to the portfolio results in there now being five unlisted holdings, 3.2% of total assets at the year end, each representing an exciting investment opportunity that is innovating in areas that are difficult to access through listed businesses alone. As detailed in the Chairman's Statement, we see increasing opportunities in the unlisted area and we are building up resource accordingly.

 

Income statement

	For the year ended 31 October 2018			For the year ended 31 October 2017
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Gains on investments	-	51,630	51,630	-	85,581	85,581
Currency gains	-	175	175	-	824	824
Income (note 2)	1,270	-	1,270	1,268	-	1,268
Investment management fee	(694)	(2,082)	(2,776)	(535)	(1,606)	(2,141)
Other administrative expenses	(737)	-	(737)	(513)	-	(513)
Net return before finance costs and taxation	(161)	49,723	49,562	220	84,799	85,019
Finance costs of borrowings	(282)	(846)	(1,128)	(250)	(749)	(999)
Net return on ordinary activities before taxation	(443)	48,877	48,434	(30)	84,050	84,020
Tax on ordinary activities	(54)	-	(54)	179	28	207
Net return on ordinary activities after taxation	(497)	48,877	48,380	149	84,078	84,227
Net return per ordinary share (note 4)	(0.95p)	93.39p	92.44p	0.30p	171.58p	171.88p

The total column of this Statement represents the profit and loss account of the Company. The supplementary revenue and capital columns are prepared under guidance published by the Association of Investment Companies.

All revenue and capital items in this statement derive from continuing operations.

A Statement of Comprehensive Income is not required as the Company does not have any other comprehensive income and the net return on ordinary activities after taxation is both the profit and comprehensive income for the year.

 

Balance sheet

	At 31 October 2018 £'000	At 31 October 2017 £'000
Fixed assets
Investments held at fair value through profit or loss	498,326	383,846
Current assets
Debtors	147	102
Cash and cash equivalents	23,607	4,686
	23,754	4,788
Creditors
Amounts falling due within one year (note 6)	(49,606)	(771)
Net current (liabilities)/assets	(25,852)	4,017
Total assets less current liabilities	472,474	387,863
Creditors
Amounts falling due after more than one year (note 6)	-	(35,024)
Net assets	472,474	352,839
Capital and reserves
Share capital	2,861	2,450
Share premium account	153,024	82,180
Special reserve	35,220	35,220
Capital reserve	280,897	232,020
Revenue reserve	472	969
Shareholders' funds	472,474	352,839
Net asset value per ordinary share (after deducting borrowings at fair value) (note 6)	825.72p	718.89p
Net asset value per ordinary share (after deducting borrowings at par)	825.79p	720.02p
Ordinary shares in issue (note 8)	57,214,739	49,004,319

 

Statement of changes in equity

For the year ended 31 October 2018

	Share  capital £'000	Share premium account £'000	Special reserve £'000	Capital* reserve £'000	Revenue reserve £'000	Shareholders' funds £'000
Shareholders' funds at 1 November 2017	2,450	82,180	35,220	232,020	969	352,839
Ordinary shares issued (note 8)	411	70,844	-	-	-	71,255
Net return on ordinary activities after  taxation	-	-	-	48,877	(497)	48,380
Shareholders' funds at 31 October 2018	2,861	153,024	35,220	280,897	472	472,474

For the year ended 31 October 2017

		Share  capital £'000	Share premium account £'000	Special reserve £'000	Capital* reserve £'000	Revenue reserve £'000	Shareholders' funds £'000
Shareholders' funds at 1 November 2016		2,450	82,180	35,220	147,942	820	268,612
Ordinary shares issued		-	-	-	-	-	-
Net return on ordinary activities after  taxation		-	-	-	84,078	149	84,227
Shareholders' funds at 31 October 2017		2,450	82,180	35,220	232,020	969	352,839

*  The capital reserve balance as at 31 October 2018 includes investment holdings gains on fixed asset investments of £21,569,000 (2017 - gains of £71,923,000).

 

Cash flow statement

	For the year ended  31 October 2018		For the year ended  31 October 2017
	£'000	£'000	£'000	£'000
Cash flows from operating activities
Net return on ordinary activities before taxation		48,434		84,020
Net gains on investments		(51,630)		(85,581)
Currency gains		(175)		(824)
Finance costs of borrowings		1,128		999
Overseas tax (incurred)/repaid		(52)		207
Changes in debtors and creditors		116		148
Cash from operations*		(2,179)		(1,031)
Interest paid		(1,083)		(1,001)
Net cash outflow from operating activities		(3,262)		(2,032)
Cash flows from investing activities
Acquisitions of investments	(118,338)		(50,072)
Disposal of investments	55,488		44,606
Net cash outflow from investing activities		(62,850)		(5,466)
Cash flows from financing activities
Shares issued	71,255		-
Borrowings drawn down	25,057		-
Borrowings repaid	(12,564)		-
Net cash inflow from financing activities		83,748		-
Increase/(decrease) in cash and cash equivalents		17,636		(7,498)
Exchange movements		1,285		(1,060)
Cash and cash equivalents at 1 November		4,686		13,244
Cash and cash equivalents at 31 October		23,607		4,686

*  Cash from operations includes dividends received of £1,086,000 (2017 - £1,159,000) and interest received of £184,000 (2017 - £102,000)

 

Twenty Largest Holdings and Twelve Month Performance at 31 October 2018

Name	Business	Country	Fair Value 2018 £'000	% of total assets*	Absolute† performance %	Relative† performance %
Ocado	Online grocery company	UK	18,588	3.5	197.7	197.2
MarketAxess	Electronic bond trading platform	USA	18,355	3.5	26.2	26.0
Wayfair	Online furniture and homeware   retailer	USA	17,989	3.4	64.1	63.9
Alnylam      Pharmaceuticals	Therapeutic gene silencing	USA	17,909	3.4	(31.5)	(31.6)
LendingTree	Online loan marketplace	USA	15,991	3.1	(21.9)	(22.0)
AeroVironment	Small unmanned aircraft systems	USA	15,529	3.0	83.0	82.7
Chegg	Online educational company	USA	12,383	2.4	83.3	83.0
Tesla, Inc	Electric cars, autonomous driving     and solar energy	USA	11,853	2.3	5.7	5.6
STAAR Surgical	Develops and manufactures high   margin visual implants	USA	11,303	2.2	214.3	213.8
Exact Sciences	Provides non-invasive molecular   tests for early cancer detection	USA	10,767	2.1	33.8	33.6
Novocure	Manufacturer of medical devices     for cancer treatment	USA	10,179	2.0	60.1	59.8
Grubhub	Online and mobile platform for   restaurant pick-up and delivery   orders	USA	10,163	2.0	58.0	57.7
Temenos Group	Banking software	Switzerland	9,850	1.9	24.4	24.2
Zillow Class C	US online real estate portal	USA	9,709	1.9	1.1	1.0
Teladoc	Telemedicine services provider	USA	9,391	1.8	117.1	116.8
iRobot	Domestic and military robots	USA	8,854	1.7	36.5	36.3
Puretech Health	IP commercialisation focused on   health care	UK	8,401	1.6	34.3	34.1
Pacira Pharmaceuticals	Development, commercialisation   and manufacturing of proprietary   pharmaceutical products	USA	7,890	1.5	58.2	58.0
IPG Photonics	High-power fibre lasers	USA	7,696	1.5	(34.9)	(35.0)
Dexcom	Real time blood glucose   monitoring	USA	7,576	1.5	206.8	206.4
			240,376	46.3

*     Total assets less current liabilities before the deduction of borrowings.

^†     Absolute and relative performance has been calculated on a total return basis over the period 1 November 2017 to 31 October 2018. Absolute performance is in sterling terms; relative performance is against S&P Global Small Cap Index (in sterling terms).

Source: Baillie Gifford/StatPro and relevant underlying index providers. See disclaimer at the end of this announcement.

Past performance is not a guide to future performance.

 

List of Investments as at 31 October 2018

Name	Business	Country	Fair Value 2018 £'000		% of total assets		Fair Value 2017 £'000
Ocado	Online grocery company	UK	18,588		3.5		5,676
MarketAxess	Electronic bond trading platform	USA	18,355		3.5		21,640
Wayfair	Online furniture and homeware retailer	USA	17,989		3.4		8,964
Alnylam Pharmaceuticals	Therapeutic gene silencing	USA	17,909		3.4		22,449
LendingTree	Online loan marketplace	USA	15,991		3.1		17,178
AeroVironment	Small unmanned aircraft systems	USA	15,529		3.0		6,774
Chegg	Online educational company	USA	12,383		2.4		3,899
Tesla, Inc	Electric cars, autonomous driving and   solar energy	USA	11,853		2.3		11,209
STAAR Surgical	Develops and manufactures high margin   visual implants	USA	11,303		2.2		3,142
Exact Sciences	Provides non-invasive molecular tests for   early cancer detection	USA	10,767		2.1		4,552
Novocure	Manufacturer of medical devices for   cancer treatment	USA	10,179		2.0		4,136
Grubhub	Online and mobile platform for restaurant    pick-up and delivery orders	USA	10,163		2.0		6,432
Temenos Group	Banking software	Switzerland	9,850		1.9		7,955
Zillow Class C	US online real estate portal	USA	9,709		1.9		5,646
Teladoc	Telemedicine services provider	USA	9,391		1.8		2,912
iRobot	Domestic and military robots	USA	8,854		1.7		9,244
Puretech Health	IP commercialisation focused on health   care	UK	8,401		1.6		4,154
Pacira Pharmaceuticals	Development, commercialisation and    manufacturing of proprietary   pharmaceutical products	USA	7,890		1.5		2,414
IPG Photonics	High-power fibre lasers	USA	7,696		1.5		14,208
Dexcom	Real time blood glucose monitoring	USA	7,576		1.5		2,470
Baozun SPN ADR	Chinese e-commerce solution provider	China	7,568		1.5		4,569
Codexis	Manufacturer of custom industrial   enzymes	USA	7,302		1.4		2,295
InfoMart Corp	Internet platform for restaurant supplies	Japan	6,306		1.2		4,388
Benefitfocus	Cloud-based benefits software provider	USA	6,280		1.2		1,947
Galapagos	Clinical stage biotechnology company	Belgium	6,208		1.2		5,640
Tandem Diabetes Care	Manufacturer of pumps for diabetic   patients	USA	6,165		1.2		-
MonotaRO	Online business supplies	Japan	6,012		1.2		3,586
Renishaw	Measurement and calibration equipment	UK	5,905		1.1		6,963
IP Group	Intellectual property commercialisation	UK	5,846		1.1		8,079
Xero	Could-based accounting software	New Zealand	5,801		1.1		4,255
Splunk	Data diagnostics	USA	5,773		1.1		2,913
Genmab	Therapeutic antibody company	Denmark	5,274		1.0		3,636
Evolent Health	Healthcare company which helps   hospitals move to value-based   healthcare	USA	5,097		1.0		-
BlackLine	Enterprise software developer	USA	5,046		1.0		-
Oxford Nanopore   Technologies‡	Novel DNA sequencing technology	UK	4,982		0.9		4,176
AxoGen Inc	A regenerative medicine company for   peripheral nerve repair	USA	4,944		0.9		-
Peptidream	Drug discovery platform	Japan	4,925		0.9		2,998
Genus	Animal breeding services	UK	4,874		0.9		5,180
Kingdee International   Software	Enterprise management software	China	4,871		0.9		3,081
Cellectis	Biotech focused on genetic engineering	France	4,723		0.9		4,942
Morphosys	Therapeutic antibodies	Germany	4,656		0.9		4,180
List of Investments as at 31 October 2018
Name	Business	Country	Fair Value 2018 £'000		% of total assets		Fair Value 2017 £'000
NuCana SPN ADR	An oncology-focused biotechnology   company	UK		4,603	0.9		2,156
ASOS	Online fashion retailer	UK		4,522	0.9		3,874
CyberArk Software	Cyber security solutions provider	Israel		4,299	0.8		-
Penumbra	Manufacturer of novel blood clot   extraction technology	USA		4,290	0.8		2,130
Faro Technologies	Designs and develops measurement   devices	USA		4,263	0.8		4,204
National Instruments Corp	Instrumentation equipment used in   research and testing	USA		4,192	0.8		3,706
ResTORbio	Clinical stage biopharmaceutical   company	USA		4,132	0.8		-
Yext	Digital knowledge manager	USA		4,024	0.8		-
Akili Interactive Labs‡	Digital medicine company	USA		3,913	0.8		-
KSQ Therapeutics‡	Biotechnology target identification   company	USA		3,913	0.8		-
Digital Garage	Internet business incubator	Japan		3,851	0.7		2,902
Jianpu Technology ADR	Chinese consumer finance marketplace	China		3,757	0.7		-
Seattle Genetics	Antibody conjugates based   biotechnology	USA		3,756	0.7		3,947
Trupanion	Pet health insurance provider	USA		3,656	0.7		3,923
ZOZO (formerly Start     Today)	Internet fashion retailer	Japan		3,630	0.7		5,083
M3	Online medical database	Japan		3,530	0.7		3,131
Adatimmune Therapeutics   ADR	Clinical stage biopharmaceutical   company	UK		3,400	0.7		2,186
Victrex	High-performance thermo-plastics	UK		3,370	0.6		3,048
Cosmo Pharmaceuticals	Therapies for gastrointestinal diseases	Italy		3,289	0.6		3,643
SEEK	Online recruitment portal	Australia		3,232	0.6		3,461
Rightmove	UK online property portal	UK		3,119	0.6		2,865
Mindbody CL	Business management software for the   wellness sector	USA		3,031	0.6		2,308
Unity Biotechnology Inc	Biotechnology company seeking to   develop anti ageing therapies	USA		2,950	0.6		1,506
Zillow Class A	US online real estate portal	USA		2,869	0.6		2,825
Ceres Power Holding	Developer of fuel cells	UK		2,729	0.5		1,995
Ambarella	Video compression and image   processing semiconductors	USA		2,654	0.5		3,124
Uxin ADR	E-commerce services provider	China		2,404	0.5		-
Spire Global‡	Manufacturer and operator of   nanosatellites for data collection	USA		2,241	0.4		2,259
Dialog Semiconductor	Analogue chips for mobile phones	Germany		2,204	0.4		3,992
SDL	Language translation services	UK		2,196	0.4		2,591
Stratasys	3D printer manufacturer	USA		2,156	0.4		2,451
Sensirion Holding AG	Manufacturer of gas and flow sensors	Switzerland		2,154	0.4		-
Oxford Instruments	Produces advanced instrumentation   equipment	UK		2,098	0.4		2,121
Horizon Discovery	Customised cell lines to aid drug   discovery	UK		1,975	0.4		2,596
Suess Microtec	Fabrication and inspection equipment	Germany		1,960	0.4		2,875
Aduro Biotechnology	Immunotherapy services provider	USA		1,938	0.3		1,302
Digimarc	Digital watermarking technology	USA		1,597	0.3		2,188
CEVA	Licenses DSP-based platforms   applications to the semiconductor   industry	USA		1,591	0.3		2,998
Ellie Mae	Provides technology solutions to   automate mortgage origination process	USA		1,555	0.3		2,032
List of Investments as at 31 October 2018
Name	Business	Country	Fair Value 2018 £'000		% of total assets		Fair Value 2017 £'000
4D Pharma	Bacteria derived novel therapeutics	UK		1,526	0.3		3,748
Reaction Engines Limited‡	Advanced heat exchange company	UK		1,500	0.3		-
Rubius Therapeutics	Developer of novel therapies using    engineered red blood cells	USA		1,406	0.3		-
Tissue Regenix	Regenerative medical devices	UK		1,344	0.2		1,430
Basware	Software solutions for financial   transactions	Finland		1,203	0.2		2,477
Nanoco	Quantum dot manufacturer	UK		1,194	0.2		732
C4X Discovery Holdings	Rational drug design and optimisation	UK		1,144	0.2		851
Catapult Group   International	Sports analytics focused on optimising   athlete performance	Australia		1,027	0.2		1,961
Ricardo	Automotive engineer	UK		969	0.2		1,123
China Financial Services	Small and medium-sized enterprises   lending in China	China		955	0.2		1,276
Avacta Group	Analytical reagents and instrumentation	UK		892	0.2		1,087
Xeros Technology Group	Polymer technology company with      laundry and textile applications	UK		860	0.2		3,733
Xaar	Ink jet printing technology	UK		838	0.2		2,794
Zumtobel	Commercial lighting	Austria		738	0.1		1,350
Acacia Research	Patent licenser	USA		569	0.1		745
Ilika	Discovery and development of materials   for mass market applications	UK		500	0.1		466
Foamix Pharmaceuticals	Drug reformulation technology	Israel		379	0.1		510
hVIVO (formerly     Retroscreen Virology)	Outsourced pre-clinical analytical   services	UK		300	0.1		400
Applied Graphene   Materials	Manufactures graphene nanoplatelets	UK		261	0.1		242
Sarine Technologies	Systems for diamond grading and   cutting	Singapore		257	0.0		462
Summit Therapeutics	Drug discovery and development	UK		255	0.0		1,065
Thin Film Electronics	Develops printed, rewritable memory   media	Norway		200	0.0		519
Velocycs	Gas to liquid technology	UK		18	0.0		162
GI Dynamics	Develops and markets medical devices	Australia		14	0.0		34
China Lumena New   Materials	Mines, processes and manufactures   natural thenardite products	China		0	0.0		0
Ensogo	South East Asian e-commerce	Australia		0	0.0		0
Total equities				498,326	95.6
Net current assets				22,776	4.4
Total assets at fair value*				521,102	100.0

*     Total assets less current liabilities before deduction of borrowings.

‡    Denotes unlisted security.

 

Distribution of total assets^* by industry

		Industry Analysis 31 October 2018 % of total assets*		Portfolio Weightings (relative to comparative index†) at 31 October 2018 % points overweight/(underweight)
Equities:	Biotechnology	15.2		12.1
	Software	12.2		8.5
	Internet and Direct Marketing Retail	11.1		10.4
	Health Care Equipment and Supplies	8.8		6.2
	Electronic Equipment, Instruments and Components	5.2		2.5
	Capital Markets	4.6		2.1
	Health Care Technology	4.5		4.0
	Life Sciences Tools and Services	4.4		3.4
	Pharmaceuticals	3.9		2.0
	Aerospace and Defence	3.3		2.0
	Interactive Media and Services	3.1		2.2
	Thrifts and Mortgage Finance	3.1		2.3
	Diversified Consumer Services	2.4		1.4
	Automobiles	2.3		2.2
	Semiconductors and Semiconductor Equipment	1.8		(0.2)
	Household Durables	1.7		0.2
	Trading Companies and Distributors	1.2		(0.4)
	Professional Services	1.0		(0.5)
	Internet and Catalogue Retail	0.9		0.9
	Consumer Finance	0.9		0.2
	Chemicals	0.7		(2.3)
	Insurance	0.7		(2.4)
	IT Services	0.7		(1.7)
	Technology Hardware, Storage and Peripherals	0.6		0.1
	Electrical Equipment	0.6		(0.3)
	Internet Software and Services	0.5		0.5
	Machinery	0.2		(4.5)
	Energy Equipment and Services	0.0		(1.4)
	Net Current Assets	4.4
Total assets*		100.0
* Total assets less current liabilities before deduction of borrowings.
† S&P Global Small Cap Index (in sterling terms). Weightings exclude industries where the Company has no exposure.
See disclaimer at the end of this announcement.

Distribution of total assets

Geographical Analysis

		31 October 2018 %	31 October 2017 %
North America		58.7	54.9
	USA	58.7	54.9
Europe		25.8	32.6
	United Kingdom	16.9	20.3
	Eurozone	4.7	9.1
	Developed Europe (non euro)	4.2	3.2
Asia		9.2	9.0
	Japan	5.4	6.6
	China	3.8	2.3
	Singapore	-	0.1
Australasia		1.9	2.5
	Australia	0.8	1.4
	New Zealand	1.1	1.1
Total equities		95.6	99.0
Net current assets		4.4	1.0
Total assets*		100.0	100.0

Sectoral Analysis

		31 October 2018 %		31 October 2017 %
Consumer Discretionary		18.4		17.2
Financials		9.3		14.7
Health Care		36.8		29.6
Industrials		6.3		6.0
Information Technology		21.0		29.9
Materials		0.7		0.9
Telecommunication Services		3.1		0.7
Net Current Assets		4.4		1.0
Total assets*		100.0		100.0

 * Total assets less current liabilities before deduction of borrowings

 

Notes
1.	The financial statements for the year to 31 October 2018 have been prepared in accordance with FRS102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' The accounting policies adopted are consistent with those of the previous financial year. In accordance with the Financial Reporting Council's guidance on going concern and liquidity risk, the Directors have undertaken a rigorous review of the Company's ability to continue as a going concern. An explanation of the Company's principal risks and how they are managed is set out on pages 8 and 9 and contained in note 17 to the Annual Report Financial Statements. The Company's assets, the majority of which are investments in quoted securities which are readily realisable, exceed its liabilities significantly. All borrowings require the prior approval of the Board. Gearing levels and compliance with borrowing covenants are reviewed by the Board on a regular basis. Accordingly, the Financial Statements have been prepared on the going concern basis as it is the Directors' opinion, having assessed the principal risks and other matters set out in the Viability Statement on page 9 of the Annual Report and Financial Statements, that the Company will continue in operational existence for a period of at least twelve months from the date of approval of these Financial Statements. The Directors consider the Company's functional currency to be sterling as the Company's shareholders are predominantly based in the UK and the Company is subject to the UK's regulatory environment.
2.	Income	2018 £'000	2017 £'000
	Income from investments	1,086	1,166
	Deposit interest	184	102
		1,270	1,268
3.	The Company has appointed Baillie Gifford & Co Limited, a wholly owned subsidiary of Baillie Gifford & Co, as its Alternative Investment Fund Manager (AIFM) and Company Secretaries. Baillie Gifford & Co Limited has delegated portfolio management services to Baillie Gifford & Co. The Management Agreement can be terminated on three months' notice. The annual management fee is 0.95% on the first £50m of net assets, 0.65% on the next £200m of net assets and 0.55% on the remaining net assets. Management fees are calculated and payable quarterly.
4.	Net return per ordinary share Revenue 2018  Capital Total Revenue 2017 Capital Total Net return on ordinary activities after     taxation (0.95p) 93.39p 92.44p 0.30p 171.58p 171.88p
	Revenue return per ordinary share is based on the net revenue loss on ordinary activities after taxation of £497,000 (2017 - net revenue profit of £149,000) and on 52,335,270 (2017 - 49,004,319) ordinary shares, being the weighted average number of ordinary shares in issue during each year. Capital return per ordinary share is based on the net capital gain for the financial year of £48,877,000 (2017 - net capital gain of £84,078,000) and on 52,335,270 (2017 - 49,004,319) ordinary shares, being the weighted average number of ordinary shares in issue during each year. There are no dilutive or potentially dilutive shares in issue.

5.         There are no dividends paid and proposed in respect of the financial year. There is no revenue available for distribution by way of dividend for the year (2018 - revenue loss of £497,000; 2017 - revenue profit of £149,000) which is the basis on which the requirements of section 1158 of the Corporation Tax Act are considered.

6.         The Company has a five year fixed rate facility with National Australia Bank Limited which expires on 30 September 2019 and a five year £25 million revolving credit facility with National Australia Bank Limited which expires on 29 June 2023. At 31 October 2018 the drawings were €9,400,000, US$25,600,000 and £7,500,000 under the fixed rate facility and €2,128,263, US$9,895,500 and £3,125,000 under the floating rate facility (31 October 2017 - €9,400,000, US$25,600,000 and £7,500,000 under the fixed rate facility, which was included in 'Creditors: amounts falling due in more than one year).

The fair value of the bank loans at 31 October 2018 was £48,669,000 (31 October 2017 - £35,574,000).

Notes (Ctd)

7.	The Company incurred transaction costs on purchases of £44,000 (2017 - £23,000) and on sales of £25,000 (2017 - £23,000).
8.	At the Annual General Meeting on 24 January 2018 the Company renewed its authority to purchase shares in the market, in respect of 7,345,747 ordinary shares (equivalent to approximately 14.99% of its issued share capital at that date). No shares were bought back during the years to 31 October 2018 or 2017. At 31 October 2018 the Company had authority to buy back 7,345,747 ordinary shares. The Company also has authority to allot shares under section 551 of the Companies Act 2006. The Board has authorised use of this authority to issue new shares at a premium to net asset value in order to enhance the net asset value per share for existing shareholders and improve the liquidity of the Company's shares. In the year to 31 October 2018 the Company issued a total of 8,210,420 shares on a non pre-emptive basis (nominal value £411,000, representing 16.8% of the issued share capital at 31 October 2017) at a premium to net asset value (on the basis of debt valued at par value) raising net proceeds of £71,255,000 (2017 - Nil).
9.	The financial information set out above does not constitute the Company's statutory accounts for the year ended 31 October 2018. The financial information for 2018 is derived from the statutory accounts for 2018 which will be delivered to the Registrar of Companies following the Company's Annual General Meeting. The financial information for 2017 is derived from the statutory accounts for 2017 which have been delivered to the Registrar of Companies. The Auditors have reported on the 2018 accounts, their report was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006.
10.	Glossary of Terms
	Total Assets
	The total value of assets held less all liabilities other than liabilities in the form of borrowings.
	Net Asset Value
	Also described as shareholders' funds, Net Asset Value (NAV) is the value of total assets less liabilities (including borrowings). The NAV per share is calculated by dividing this amount by the number of ordinary shares in issue.
	Net Asset Value (Borrowings at Fair Value)#
	Borrowings are valued at an estimate of their market worth. The value of the borrowings at book and fair value are set out on page 52 of the Annual Report and Financial Statements.
	Net Asset Value (Borrowings at Par Value)#
	Borrowings are valued at their nominal par value. The value of the borrowings at book and fair value are set out on page 52 of the Annual Report and Financial Statements.
	Net Liquid Assets Net liquid assets comprise current assets less current liabilities, excluding borrowings.
	Discount/Premium#
	As stock markets and share prices vary, an investment trust's share price is rarely the same as its NAV. When the share price is lower than the NAV per share it is said to be trading at a discount. The size of the discount is calculated by subtracting the share price from the NAV per share and is usually expressed as a percentage of the NAV per share. If the share price is higher than the NAV per share, this situation is called a premium.
	Total Return
	The total return is the return to shareholders after reinvesting the net dividend on the date that the share price goes ex-dividend.
	Ongoing Charges
	The total expenses (excluding borrowing costs) incurred by the Company as a percentage of the average net asset value (with debt at fair value).
	Notes (Ctd) Glossary of Terms (Continued) Gearing
	At its simplest, gearing is borrowing. Just like any other public company, an investment trust can borrow money to invest in additional investments for its portfolio. The effect of the borrowing on the shareholders' assets is called 'gearing'. If the Company's assets grow, the shareholders' assets grow proportionately more because the debt remains the same. But if the value of the Company's assets falls, the situation is reversed. Gearing can therefore enhance performance in rising markets but can adversely impact performance in falling markets.
	Gearing is the Company's borrowings at par less cash and cash equivalents expressed as a percentage of shareholders' funds.
	Potential gearing is the Company's borrowings expressed as a percentage of shareholders' funds.
	Leverage
	For the purposes of the Alternative Investment Fund Managers Directive, leverage is any method which increases the Company's exposure, including the borrowing of cash and the use of derivatives. It is expressed as a ratio between the Company's exposure and its net asset value and can be calculated on a gross and a commitment method. Under the gross method, exposure represents the sum of the Company's positions after the deduction of sterling cash balances, without taking into account any hedging and netting arrangements. Under the commitment method, exposure is calculated without the deduction of sterling cash balances and after certain hedging and netting positions are offset against each other.
	Active Share#
	Active share, a measure of how actively a portfolio is managed, is the percentage of the portfolio that differs from its comparative index. It is calculated by deducting from 100 the percentage of the portfolio that overlaps with the comparative index. An active share of 100 indicates no overlap with the index and an active share of zero indicates a portfolio that tracks the index.
	Compound Annual Return
	The compound annual return converts the return over a period of longer than one year to a constant annual rate of return applied to the compound value at the start of each year.
	Unlisted Company
	An unlisted company means a company whose shares are not available to the general public for trading and not listed on a stock exchange. # Alternative performance measure which is considered to be a known industry metric.
11.	The Annual Report and Financial Statements will be available on the Edinburgh Worldwide page of the Managers' website http://www.edinburghworldwide.co.uk† on or around 18 December 2018.

†          Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on    

           the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

Third Party Data Provider Disclaimer

No third party data provider ('Provider') makes any warranty, express or implied, as to the accuracy, completeness or timeliness of the data contained herewith nor as to the results to be obtained by recipients of the data. No Provider shall in any way be liable to any recipient of the data for any inaccuracies, errors or omissions in the index data included in this document, regardless of cause, or for any damages (whether direct or indirect) resulting therefrom.

No Provider has any obligation to update, modify or amend the data or to otherwise notify a recipient thereof in the event that any matter stated herein changes or subsequently becomes inaccurate.

Without limiting the foregoing, no Provider shall have any liability whatsoever to you, whether in contract (including under an

indemnity), in tort (including negligence), under a warranty, under statute or otherwise, in respect of any loss or damage suffered by you as a result of or in connection with any opinions, recommendations, forecasts, judgments, or any other conclusions, or any course of action determined, by you or any third party, whether or not based on the content, information or materials contained herein.

S&P Index Data

The S&P Global Small Cap Index ('Index') is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ('SPDJI'). Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ('S&P'); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ('Dow Jones'). Neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors make any representation or warranty, express or implied, as to the ability of any index to accurately represent the asset class or market sector that it purports to represent and neither S&P Dow Jones Indices LLC, Dow Jones Trademark Holdings LLC, their affiliates nor their third party licensors shall have any liability for any errors, omissions, or interruptions of any index or the data included therein.

- Ends -

 

END

 

 

FR FKNDDOBDDBBD